RNS Number : 3732X
Acambis PLC
24 June 2008
Company Secretary change
Cambridge, UK and Cambridge, Massachusetts - 24 June 2008 - Acambis plc (Acambis) (LSE: ACM) announces that, with effect from 23 June 2008, Sarah Gowing has been appointed Company Secretary of Acambis.
-ends-
Enquiries:
Acambis plc
Ian Garland, Chief Executive Officer
Elizabeth Jones, Chief Financial Officer
Lyndsay Wright, VP, Communications and IR
Tel: +44 (0) 1223 275 300
Brunswick
Jon Coles / Justine McIlroy / Annabel Entress
Tel: +44 (0) 20 7404 5959
About Acambis
Acambis is a vaccine company developing novel vaccines that address significant unmet medical needs or substantially improve standards of care. It has a broad pipeline of novel vaccine candidates, including:
§ the only single-dose vaccine in development against Japanese encephalitis (JE);
§ the leading vaccine in development against the West Nile virus;
§ a tetravalent dengue vaccine that has achieved proof-of-concept by generating 100% seroconversion to all four
dengue virus serotypes;
§ the only vaccine in development against Clostridium difficile bacteria, a leading case of hospital-acquired infections;
§ a novel influenza vaccine that provides a universal approach to tackling ‘A’ strains of the virus; and
§ a replication-deficient vaccine, dl5-29, against genital herpes.
Acambis has partnerships with sanofi pasteur for the development and commercialisation of the JE, West Nile and dengue vaccines. These are based on Acambis' proprietary ChimeriVax™ technology, which was developed in association with St Louis University.
Acambis is recognised internationally as the leading producer of smallpox vaccines for emergency-use stockpiles held by the US Government and several other governments around the world. Acambis developed its ACAM2000™ smallpox vaccine under contracts with the US Government.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US, and is listed on the London Stock Exchange (ACM). More information is available at www.acambis.com.
'Safe Harbour' statement
Statements contained within this news release may contain forward-looking comments, which involve risks and uncertainties that may cause actual results to vary from those contained in the forward-looking statements. In some cases, you can identify such forward-looking statements by terminology such as 'may', 'will', 'could', 'forecasts', 'expects', 'plans', 'anticipates', 'believes', 'estimates', 'predicts', 'potential', or 'continue'. Predictions and forward-looking references in this news release are subject to the satisfactory progress of research which is, by its very nature, unpredictable. Forward projections reflect management's best estimates based on information available at the time of issue.
This information is provided by RNS
The company news service from the London Stock Exchange
END
COSVZLBLVQBBBBX